Overview
- On May 5, 2026 Embecta reported a revenue drop of about 14%, cut full-year adjusted EPS guidance by roughly 43% at the midpoint, and reduced its quarterly dividend from $0.15 to $0.01, prompting an approximate 57.8% one-day share price collapse.
- A securities class action was filed in federal court in New Jersey alleging Embecta misrepresented the commercial stability of its insulin pen-needle business and presented unreliable fiscal guidance.
- Several national plaintiff firms have publicly opened investigations and are actively recruiting investors to move for lead-plaintiff appointment ahead of the August 17, 2026 deadline.
- No class has been certified and no lead plaintiff has been appointed so investors are not represented by class counsel unless they retain counsel or a lead plaintiff is named; the lead plaintiff will select counsel and direct discovery and litigation strategy.
- The complaint alleges specific commercial problems—competitive share loss at a major customer and retail-channel volume weakness in pen-needle sales—and the case could determine whether harmed retail and institutional investors recover losses if defendants are found liable.